Spectral AI, Inc. announced that it has achieved 100% pediatric patient enrollment at burn centers for its 2024 pivotal study designed to validate the AI-driven algorithm used by its DeepView System for its burn indication. This pivotal study is scheduled to be completed in the fourth quarter of 2024 and is the final clinical trial before the Company seeks FDA approval of its DeepView System for burn indication in 2025. Spectral AI?s DeepView System utilizes proprietary multispectral imaging, trained and tested against a proprietary database of more than 340 billion clinically validated data points to distinguish between healthy and damaged tissue.

The DeepView System can be used immediately upon a child?s arrival to the emergency department or burn center, providing immediate and accurate wound assessments in support of timely clinical decision-making for burn injuries. The procedure is non-invasive and because it is cart-based, the DeepView System can be brought to the patient, thus alleviating any potential trauma associated with moving an injured child.